# Mayne Pharma expands manufacturing capacity with $4.8M grant

Mayne Pharma will receive up to $4.8 million to expand its advanced manufacturing capability, aiming to double production of chronic pain medications, boost encapsulation capacity from 56 million to 104 million doses per year, and increase blister packaging capacity from 7.9 million to 21.3 million boxes per year.

- Type: Expansion
- Announced: 2022-05-11
- Where: Australia
- Value: $3.40M (4.80M AUD)
- Status: announced
- Capacity: 104 million doses per year (encapsulation), 21.3 million boxes per year (blister packaging)
- Products: chronic pain medications, Kapanol
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Mayne Pharma](https://endata.com/companies/62803.md)

## Sources

- [bulkhandlingreview.com.au](https://www.bulkhandlingreview.com.au/federal-funding-for-concrete-and-glass-manufacturing/), 2022-05-11: "This funding is a big win for jobs and another vote of confidence in South Australia’s advanced manufacturing capability."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.